Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.41 |
| ▸ | SELE | P16581 | 1/20 | 0.41 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5962918 | 0.87 | NOTUM (0.55) | NOTUMNPC1GLARAB9ASMN1; SMN2 | |
| SCHEMBL14541930 | 0.86 | NOTUM (0.53) | NOTUMNPC1GLARAB9ASMN1; SMN2 | |
| Diphenylether SCHEMBL28989276 | 0.83 | MAPK1 (0.51) | NOTUMNPC1GLARAB9ASMN1; SMN2 | |
| SCHEMBL27250 | 0.82 | NOTUM (0.65) | NOTUMNPC1GLARAB9ASMN1; SMN2 | |
| SCHEMBL4341894 | 0.82 | NOTUM (0.78) | NOTUMNPC1KDM4EALDH1A1MAPK1 | |
| SCHEMBL7657790 | 0.80 | NOTUM (0.51) | NOTUMKDM4EALDH1A1MAPK1MEN1 | |
| SCHEMBL514704 | 0.80 | NOTUM (0.63) | NOTUMNPC1GLARAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL15510676 | 0.80 | NOTUM (0.63) | NOTUMNPC1GLARAB9ASMN1; SMN2 | |
| SCHEMBL28493417 | 0.80 | NOTUM (0.63) | NOTUMNPC1GLARAB9ASMN1; SMN2 | |
| SCHEMBL6428811 | 0.80 | NOTUM (0.63) | NOTUMNPC1GLARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105732638-B | A kind of bruton's tyrosine kinase inhibitor with loop coil or caged scaffold and preparation method thereof | 成都倍特药业有限公司 | 2018-01-30 | — | — | CN | claimed |
| US-20230167067-A1 | PHOTOREDOX-CATALYZED DIRECT C-H FUNCTIONALIZATION OF ARENES | UNIV NORTH CAROLINA CHAPEL HILL (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230167067-A1 | PHOTOREDOX-CATALYZED DIRECT C-H FUNCTIONALIZATION OF ARENES | UNIV NORTH CAROLINA CHAPEL HILL (US) | 2023-06-01 | — | — | US | disclosed |
| US-11584720-B2 | Photoredox-catalyzed direct C-H functionalization of arenes | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2023-02-21 | — | — | US | disclosed |
| US-10399947-B2 | Photoredox-catalyzed direct C—H functionalization of arenes | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2019-09-03 | — | — | US | disclosed |
| CN-107501270-B | A kind of compound containing sulphonyl ethylene imine structure, pharmaceutical composition and its application | 宏腾建设集团有限公司 | 2019-06-28 | — | — | CN | disclosed |
| US-20180148414-A1 | PHOTOREDOX-CATALYZED DIRECT C-H FUNCTIONALIZATION OF ARENES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2018-05-31 | — | — | US | disclosed |
| US-20180148414-A1 | PHOTOREDOX-CATALYZED DIRECT C-H FUNCTIONALIZATION OF ARENES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2018-05-31 | — | — | US | disclosed |
| CN-107501270-A | A kind of compound containing sulphonyl ethylene imine structure, pharmaceutical composition and its application | 南京宏腾建设工程有限公司 | 2017-12-22 | — | — | CN | disclosed |
| CN-106153797-B | It is a kind of to replace Buddhist nun's preparation Related substance method according to Shandong for Buddhist nun and according to Shandong | 北京睿创康泰医药研究院有限公司 | 2017-08-29 | — | — | CN | disclosed |
| CN-106153798-B | It is a kind of to be used to analyze the purposes for doing reference standard about the HPLC methods and these impurity of material for Buddhist nun's preparation according to Shandong for Buddhist nun and according to Shandong | 北京睿创康泰医药研究院有限公司 | 2017-08-29 | — | — | CN | disclosed |
| WO-2016196816-A1 | PHOTOREDOX-CATALYZED DIRECT C-H FUNCTIONALIZATION OF ARENES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2016-12-08 | — | — | WO | disclosed |
| CN-106083860-A | A kind of synthesis and purifying process replacing Buddhist nun's intermediate according to Shandong | 艾美科健（中国）生物医药有限公司 | 2016-11-09 | — | — | CN | disclosed |
| CN-105153154-A | BTK (bruton tyrosine kinase) inhibitor and purpose of BTK inhibitor | GUANGDONG HEC PHARMACEUTICAL | 2015-12-16 | — | — | CN | disclosed |
| CN-1520298-A | Pyrazolopyrimidines as therapeutic agents | �����ʩ���عɷݹ�˾ | 2004-08-11 | — | — | CN | disclosed |
| CN-1147492-C | New metal protease inhibitors, its preparing method and their medicinal composition containing them | ɪά��ʵ���� | 2004-04-28 | — | — | CN | disclosed |
| EP-1065209-B1 | Metalloprotease inhibitors, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2003-05-02 | — | — | EP | disclosed |
| CN-1390219-A | Pyrazolopyrimidines as therapeutic agents | ABBOTT AG (DE) | 2003-01-08 | — | — | CN | disclosed |
| US-6339092-B1 | FOR THERAPY RHEUMATOID ARTHRITIS, ARTHROSIS, TUMOUR INVASION AND GROWTH, INCLUDING MALIGNANT SPREAD AND THE FORMATION OF METASTASES, ULCERATIONS, ATHEROSCLEROSIS | ADIR ET COMPAGNIE (FR) | 2002-01-15 | — | — | US | disclosed |
| EP-1065209-A1 | Metalloprotease inhibitors, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584720-B2 | Photoredox-catalyzed direct C-H functionalization of arenes | PPOX, AOC2, AOC3 | NOTUM 3331/4885NPC1 1847/4885GLA 4069/4885 |
| US-10399947-B2 | Photoredox-catalyzed direct C—H functionalization of arenes | PPOX, AOC2, AOC3 | NOTUM 3386/4885NPC1 1903/4885GLA 4053/4885 |
| US-20180148414-A1 | PHOTOREDOX-CATALYZED DIRECT C-H FUNCTIONALIZATION OF ARENES | PPOX, AOC2, AOC3 | NOTUM 3331/4885NPC1 1847/4885GLA 4069/4885 |
| US-20230167067-A1 | PHOTOREDOX-CATALYZED DIRECT C-H FUNCTIONALIZATION OF ARENES | PPOX, AOC2, AOC3 | NOTUM 3331/4885NPC1 1847/4885GLA 4069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.